{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:55:43Z","timestamp":1767135343660,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd011397","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2015,8,24]],"date-time":"2015-08-24T00:00:00Z","timestamp":1440374400000}}],"reference-count":68,"publisher":"Wiley","issue":"8","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011397.pub2","type":"journal-article","created":{"date-parts":[[2015,8,24]],"date-time":"2015-08-24T13:25:16Z","timestamp":1440422716000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS alone for adults with asthma"],"prefix":"10.1002","volume":"2015","author":[{"given":"Debbie E","family":"Anderson","sequence":"first","affiliation":[{"name":"University of Strathclyde; Strathclyde Institute of Pharmacy and Biomedical Sciences; Glasgow UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayleigh M","family":"Kew","sequence":"additional","affiliation":[{"name":"St George's, University of London; Population Health Research Institute; Cranmer Terrace London UK SW17 0RE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne C","family":"Boyter","sequence":"additional","affiliation":[{"name":"University of Strathclyde; Strathclyde Institute of Pharmacy and Biomedical Sciences; Glasgow UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,8,24]]},"reference":[{"issue":"2","key":"10.1002\/14651858.CD011397.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jaci.2011.06.004","article-title":"Tiotropium is non inferior to salmeterol in maintaining improved lung function in B16-Arg\/Arg patients with asthma","volume":"128","author":"Bateman","year":"2011","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0002|cit2","doi-asserted-by":"crossref","unstructured":"Dahl R Bateman ED Casale T Pizzichini E Vandewalker M Virchow JC Once-daily tiotropium Respimat as add-on to at least medium- to high-dose ICS, with or without LABA, improves lung function in patients with symptomatic asthma, independent of allergic status 33rd Congress of the European Academy of Allergy and Clinical Immunology, Copenhagen 2014 515","DOI":"10.1136\/thoraxjnl-2014-206260.357"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0003|cit3","unstructured":"NCT00350207 A 16-week randomised, placebo-controlled, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of tiotropium inhalation solution delivered by the Respimat inhaler (2 actuations of 2.5 mcg once daily) with that of salmeterol from the hydrofluoroalkane metered dose inhaler (2 actuations of 25 mcg twice daily) in moderate persistent asthma patients with the B16-Arg\/Arg genotype http:\/\/www.clinicaltrials.gov\/show\/NCT00350207"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0004|cit4","unstructured":"Kerstjens HAM Casale TB Bleecker ER Meltzer EO Pizzichini E Schmidt O Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled,parallel-group, active-comparator, randomised trials Lancet Respiratory Medicine"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0005|cit5","unstructured":"NCT01172808 A Phase III Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat \u00ae Inhaler (2.5 and 5 mcg Once Daily) Compared With Placebo and Salmeterol HFA MDI (50 mcg Twice Daily) Over 24 Weeks in Moderate Persistent Asthma http:\/\/www.clinicaltrials.gov\/show\/NCT01172808"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0006|cit6","first-page":"377","article-title":"Phase III trials to investigate tiotropium as add-on therapy to inhaled corticosteroids for patients with symptomatic asthma: trial design and planned statistical analyses","volume":"68","author":"Casale","year":"2013","journal-title":"Allergy"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD011397.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"AB5","DOI":"10.1016\/j.jaci.2013.12.040","article-title":"Tiotropium Respimat add-on therapy reduces airflow obstruction in patients with symptomatic moderate asthma, independent of Th2 inflammatory status","volume":"133","author":"Casale","year":"2014","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0008|cit8","unstructured":"Kerstjens HAM Casale TB Bleecker ER Meltzer EO Pizzichini E Schmidt O Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials Lancet Respiratory Medicine"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0009|cit9","unstructured":"NCT01172821 A Phase III Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat \u00ae Inhaler (2.5 and 5 mcg Once Daily) Compared With Placebo and Salmeterol HFA MDI (50 mcg Twice Daily) Over 24 Weeks in Moderate Persistent Asthma http:\/\/www.clinicaltrials.gov\/show\/NCT01172821"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0010|cit10","unstructured":"NCT01316380 A phase III, randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat \u00ae inhaler (2.5 mcg and 5 mcg once daily) compared to placebo over 12 weeks in mild persistent asthma http:\/\/www.clinicaltrials.gov\/show\/NCT01316380"},{"issue":"Suppl 57","key":"10.1002\/14651858.CD011397.pub2-BIB0011|cit11","first-page":"877s [P4133]","article-title":"Phase III trial of tiotropium as add-on therapy to low-dose inhaled corticosteroids for patients with symptomatic mild persistent asthma: design and planned analyses [Abstract]","volume":"42","author":"Paggiaro","year":"2013","journal-title":"European Respiratory Journal"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD011397.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"AB4","DOI":"10.1016\/j.jaci.2013.12.039","article-title":"Tiotropium Respimat add-on to inhaled corticosteroids improves lung function in patients with symptomatic mild asthma: results from a phase III trial","volume":"133","author":"Paggiaro","year":"2014","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0013|cit13","unstructured":"NCT01340209 A phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate safety and efficacy of tiotropium inhalation solution delivered via Respimat inhaler (2.5 and 5 \u00b5g once daily) compared with placebo over 52 weeks in patients with moderate to severe persistent asthma http:\/\/www.clinicaltrials.gov\/show\/NCT01340209"},{"issue":"4","key":"10.1002\/14651858.CD011397.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"e0124109","DOI":"10.1371\/journal.pone.0124109","article-title":"Long-term once daily tiotropium Respimat is well tolerated and maintains efficacy over 52 weeks in patients with symptomatic asthma in Japan: a randomised, placebo-controlled study","volume":"10","author":"Ohta","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0015|cit15","unstructured":"Chest Research Foundation A clinical trial comparing bronchodilator effects of two drugs, tiotropium bromide and formoterol fumarate, each over 24 hours in subjects with asthma http:\/\/apps.who.int\/trialsearch\/Trial2.aspx?TrialID=CTRI\/2008\/091\/000306"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0016|cit16","unstructured":"Ilango Dr K A clinical trial to study the effects of few anti asthmatic drug combinations on asthma patients http:\/\/apps.who.int\/trialsearch\/Trial2.aspx?TrialID=CTRI\/2012\/08\/002915"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0017|cit17","unstructured":"Boehringer Ingelheim Pharma GmbH Co. KG The effect of tiotropium-bromide on deep inspiration-induced bronchodilation and airway responsiveness in asthma - Tiotropium-bromide and lung mechanics http:\/\/apps.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2006-003385-34-NL"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0018|cit18","unstructured":"Saitama Medical University Randomized clinical study with tiotropium and formoterol\/budesonide in COPD with asthma http:\/\/apps.who.int\/trialsearch\/Trial2.aspx?TrialID=JPRN-UMIN000003618"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0019|cit19","unstructured":"EACC (Ehime Asthma COPD Conference) Add-on therapy for COPD receiving inhaled bronchodilators http:\/\/apps.who.int\/trialsearch\/Trial2.aspx?TrialID=JPRN-UMIN000005459"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0020|cit20","unstructured":"Fukuoka National Hospital Study for effects of tiotropium on smokers and non-smokers with bronchial asthma http:\/\/apps.who.int\/trialsearch\/Trial2.aspx?TrialID=JPRN-UMIN000010352"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0021|cit21","first-page":"91A","article-title":"Tiotropium as add-on therapy to ICS+LABA in patients with symptomatic severe asthma: spirometric assessment over 24 hours [Abstract]","volume":"144","author":"Corren","year":"2013","journal-title":"American College of Chest Physicians"},{"issue":"13","key":"10.1002\/14651858.CD011397.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1208606","article-title":"Tiotropium in asthma poorly controlled with standard combination therapy","volume":"367","author":"Kerstjens","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD011397.pub2-BIB0023|cit23","first-page":"AB1","article-title":"Efficacy of tiotropium in patients with asthma in relation to allergic status [Abstract]","volume":"131","author":"Vandewalker","year":"2013","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0024|cit24","unstructured":"NCT00546234 Assessing treatment options for smokers with asthma www.clinicaltrials.gov\/show\/NCT00546234"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0025|cit25","unstructured":"National Jewish Health Examining the link between obesity, inflammation, and response to asthma medications https:\/\/clinicaltrials.gov\/show\/NCT00557180"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0026|cit26","unstructured":"NCT00557700 Study to investigate the effect of inhaled tiotropium bromide on neurokinin-A induced bronchoconstriction in patients with mild-to-moderate asthma www.clinicaltrials.gov\/show\/NCT00557700"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0027|cit27","unstructured":"NCT00706446 Genotype stratified treatment with anticholinergic vs. beta-agonist (long-acting) and exacerbations (GABLE) www.clinicaltrials.gov\/show\/NCT00706446"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0028|cit28","unstructured":"NCT00772538 A phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat \u00ae inhaler (5 mcg\/day) over 48 weeks as add-on controller therapy on top of usual care in patients with severe persistent asthma www.clinicaltrials.gov\/show\/NCT00772538"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0029|cit29","unstructured":"NCT00776984 A phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat \u00ae inhaler (5 mcg\/day) over 48 weeks as add-on controller therapy on top of usual care in patients with severe persistent asthma www.clinicaltrials.gov\/show\/NCT00776984"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0030|cit30","unstructured":"NCT01290874 Blacks and exacerbations on LABA vs. tiotropium (BELT) www.clinicaltrials.gov\/show\/NCT01290874"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0031|cit31","unstructured":"NCT01573624 A multi-center, randomized, double-blind, dose-ranging study to evaluate GSK573719 in combination with fluticasone furoate, fluticasone furoate alone, and an active control of fluticasone furoate\/vilanterol combination in subjects with asthma www.clinicaltrials.gov\/show\/NCT01573624"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0032|cit32","unstructured":"NCT01641692 A multi-national, randomized, double-blind, placebo-controlled, 3-period crossover study with GSK 573719 as monotherapy in adult subjects with asthma www.clinicaltrials.gov\/show\/NCT01641692"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0033|cit33","unstructured":"NCT01696214 SAPS: Smoking Asthmatics Pilot Study www.clinicaltrials.gov\/show\/NCT01696214"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0034|cit34","unstructured":"NCT02066298 Steroids in eosinophil negative asthma www.clinicaltrials.gov\/show\/NCT02066298"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0035|cit35","unstructured":"NCT02127697 A randomized, double-blind, parallel group, 52-week study evaluating the efficacy, safety and tolerability of NVA237 in patients with poorly controlled asthma www.clinicaltrials.gov\/show\/NCT02127697"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011397.pub2-BIB0036|cit36","first-page":"2 [O5]","article-title":"Once-daily tiotropium in adolescents with symptomatic asthma despite inhaled corticosteroid treatment: a dose-ranging study [Abstract]","volume":"4","author":"Vogelberg","year":"2014","journal-title":"Clinical and Translational Allergy"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0037|cit37","unstructured":"Asthma UK Asthma Facts and FAQs http:\/\/www.asthma.org.uk\/asthma-facts-and-statistics"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1183\/09031936.96.09040636","article-title":"The costs of asthma","volume":"9","author":"Barnes","year":"1996","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1465-9921-15-61","article-title":"Tiotropium Respimat\u00ae in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma","volume":"15","author":"Beeh","year":"2014","journal-title":"Respiratory Research"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/JAA.S38841","article-title":"Tiotropium in asthma: a systematic review","volume":"7","author":"Befekadu","year":"2014","journal-title":"Journal of Asthma and Allergy"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0041|cit41","unstructured":"Brozek J Oxman A Sch\u00fcnemann H GRADEpro 2008"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0042|cit42","unstructured":"British Thoracic Society\/Scottish Intercollegiate Guidelines Network (BTS\/SIGN) British Guideline on the Management of Asthma https:\/\/www.brit-thoracic.org.uk\/guidelines-and-quality-standards\/"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0043|cit43","unstructured":"Centers for Disease Control and Prevention Asthma Surveillance Data http:\/\/www.cdc.gov\/asthma\/"},{"issue":"2","key":"10.1002\/14651858.CD011397.pub2-BIB0044|cit44","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009611.pub3","article-title":"Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults","author":"Chauhan","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD011397.pub2-BIB0045|cit45","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003137.pub5","article-title":"Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma","author":"Chauhan","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0046|cit46","unstructured":"The Alfred Hospital Monash University National ICT Australia and the University of London Covidence 2013"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0047|cit47","unstructured":"Department of Health An outcomes strategy for COPD and asthma: NHS companion document https:\/\/www.gov.uk\/government\/publications\/an-outcomes-strategy-for-copd-and-asthma-nhs-companion-document"},{"issue":"4","key":"10.1002\/14651858.CD011397.pub2-BIB0048|cit48","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005533.pub2","article-title":"Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma","author":"Ducharme","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0049|cit49","unstructured":"Boehringer Ingelheim Limited Summary of product characteristics: Spiriva 18 microgram inhalation powder, hard capsule https:\/\/www.medicines.org.uk\/emc\/medicine\/10039"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0050|cit50","unstructured":"Boehringer Ingelheim Limited Summary of product characteristics: Spiriva Respimat 2.5 micrograms solution for inhalation https:\/\/www.medicines.org.uk\/emc\/medicine\/20134"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0051|cit51","unstructured":"Electronic Medicines Compendium License extension 19th September 2014: Spiriva Respimat 2.5 micrograms solution for inhalation https:\/\/www.medicines.org.uk\/emc\/history\/20134"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0052|cit52","unstructured":"Almirall Limited Sumary of product characteristics: Eklira Genuair 322 micrograms inhalation powder https:\/\/www.medicines.org.uk\/emc\/medicine\/27001"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0053|cit53","unstructured":"Global Initiative for Asthma Global Strategy for Asthma Management and Prevention 2014 http:\/\/www.ginasthma.org\/local\/uploads\/files\/GINA_Report_2014_Aug12.pdf"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0054|cit54","unstructured":"Global Initiative for Asthma Global Strategy for Asthma Management and Prevention-Revised 2014 http:\/\/www.ginasthma.org\/local\/uploads\/files\/GINA_Report_2014_Aug12.pdf"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0055|cit55","unstructured":"International Union Against Tuberculosis and Lung Disease The Global Asthma Report 2011 http:\/\/www.theunion.org\/what-we-do\/publications\/english\/global_asthma_report2011.pdf"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0056|cit56","unstructured":"Masoli M Fabian D Holt S Beasley R Global Burden of Asthma http:\/\/www.ginasthma.org\/local\/uploads\/files\/GINABurdenReport_1.pdf"},{"issue":"1","key":"10.1002\/14651858.CD011397.pub2-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/1465-9921-7-73","article-title":"Muscarinic receptor signalling in the pathophysiology of asthma and COPD","volume":"7","author":"Gosens","year":"2006","journal-title":"Respiratory Research"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0058|cit58","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011 www.cochrane-handbook.org"},{"issue":"7","key":"10.1002\/14651858.CD011397.pub2-BIB0059|cit59","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009285.pub3","article-title":"Tiotropium versus placebo for chronic obstructive pulmonary disease","author":"Karner","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD011397.pub2-BIB0060|cit60","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011438.pub2","article-title":"Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta2-agonists (LABA) for adults with asthma","author":"Kew","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0061|cit61","unstructured":"National Institute of Health and Care Excellence Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care CG101 http:\/\/www.nice.org.uk\/guidance\/CG101"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1056\/NEJMoa1008770","article-title":"Tiotropium bromide step-up therapy for adults with uncontrolled asthma","volume":"363","author":"Peters","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0063|cit63","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"2","key":"10.1002\/14651858.CD011397.pub2-BIB0064|cit64","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1378\/chest.14-1698","article-title":"What is the role of tiotropium in asthma?: a systematic review with meta-analysis","volume":"147","author":"Rodrigo","year":"2015","journal-title":"Chest"},{"issue":"5","key":"10.1002\/14651858.CD011397.pub2-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"654","DOI":"10.4187\/respcare.02703","article-title":"Tiotropium versus placebo for inadequately controlled asthma: a meta-analysis","volume":"59","author":"Tian","year":"2014","journal-title":"Respiratory Care"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0066|cit66","doi-asserted-by":"crossref","unstructured":"Timmer W Moroni-Zentgraf P Cornelissen P Unseld A Pizzichini E Buhl R Once-daily tiotropium Respimat \u00ae 5 \u03bcg is an efficacious 24-h bronchodilator in adults with symptomatic asthma Respiratory Medicine 2014 [Epub ahead of print] 10.1016\/j.rmed.2014.12.005","DOI":"10.1016\/j.rmed.2014.12.005"},{"key":"10.1002\/14651858.CD011397.pub2-BIB0067|cit67","article-title":"Global surveillance, prevention and control of chronic respiratory diseases: A comprehensive approach","volume-title":"Global Surveillance, Prevention and Control of Chronic Respiratory Diseases: A Comprehensive Approach","author":"World Health Organization","year":"2007"},{"issue":"11","key":"10.1002\/14651858.CD011397.pub2-BIB0068|cit68","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011397","article-title":"Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS for adults with asthma","author":"Allison","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD011397.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,12]],"date-time":"2021-12-12T13:32:46Z","timestamp":1639315966000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011397.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Airways Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,8,24]]},"references-count":68,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2015,8]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011397.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,24]]}}}